Physician profile
Julia Wu
NPI 1598057234
$43,259.62
in general payments reported to CMS, 2019-2025
20 companies · $7,274 in 2025
The $7,274 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $910 · 2021: $1,180 · 2022: $14K · 2023: $14K · 2024: $5,143 · 2025: $7,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $2,938 · Consulting Fee: $2,000 · Travel and Lodging: $502 · Education: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,385.00 |
| Food and Beverage | $2,937.78 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $502.32 |
| Education | $258.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $19,410.08 | 2020-2025 | Bimzelx |
| Incyte Corporation | $17,037.20 | 2021-2023 | Opzelura |
| Epi Health, LLC | $1,500.00 | 2022 | |
| Abbvie INC. | $1,092.35 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $847.35 | 2019-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $710.17 | 2019-2025 | Siliq, Arazlo, Jublia |
| Sun Pharmaceutical Industries INC. | $467.70 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $412.54 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $391.85 | 2021-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $243.86 | 2021-2025 | |
| Lilly USA, LLC | $220.90 | 2019-2023 | Olumiant, Taltz |
| Arcutis Biotherapeutics, INC. | $203.55 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.00 | 2023 | |
| Genzyme Corporation | $125.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $106.90 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $100.95 | 2019-2024 | Adbry |
| Takeda Pharmaceuticals U.S.A., INC. | $89.00 | 2023 | |
| Pfizer INC. | $84.24 | 2021-2024 | |
| Smith+Nephew, INC. | $42.32 | 2023 | Grafix Pl, Oasis |
| Regeneron Pharmaceuticals, INC. | $28.66 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.